An international multi-disciplinary consortium of 11 partners, in which 5 leading academic institutes, 4 cutting-edge biotech companies and 2 excellent service providers will join forces to advance the treatment of cancer using an innovative immunotherapeutic nanomedicin, has received an €8.3 million Horizon 2020 grant (grant agreement No 686089).
The PRECIOUS consortium will be coordinated by the awarded Prof. Dr. Carl Figdor, senior professor in Experimental Immunology and head of the Tumor Immunology Departmentof the Radboud University Medical Center, the Netherlands.